Mark E. Duggan

3.9k total citations
46 papers, 2.6k citations indexed

About

Mark E. Duggan is a scholar working on Molecular Biology, Immunology and Allergy and Cellular and Molecular Neuroscience. According to data from OpenAlex, Mark E. Duggan has authored 46 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 13 papers in Immunology and Allergy and 10 papers in Cellular and Molecular Neuroscience. Recurrent topics in Mark E. Duggan's work include Cell Adhesion Molecules Research (13 papers), Receptor Mechanisms and Signaling (11 papers) and Neuroscience and Neuropharmacology Research (9 papers). Mark E. Duggan is often cited by papers focused on Cell Adhesion Molecules Research (13 papers), Receptor Mechanisms and Signaling (11 papers) and Neuroscience and Neuropharmacology Research (9 papers). Mark E. Duggan collaborates with scholars based in United States, Sweden and United Kingdom. Mark E. Duggan's co-authors include Michele Potashman, George D. Hartman, Craig W. Lindsley, Zhijian Zhao, Joel R. Huff, R. Robinson, Hans E. Huber, Deborah Defeo-Jones, Stanley F. Barnett and Raymond E. Jones and has published in prestigious journals such as Journal of Neuroscience, PLoS ONE and The FASEB Journal.

In The Last Decade

Mark E. Duggan

46 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark E. Duggan United States	26	1.6k	741	713	306	271	46	2.6k
Christiane Garbay France	34	2.0k 1.3×	875 1.2×	343 0.5×	280 0.9×	574 2.1×	122	3.2k
Xin-Yun Huang United States	24	2.2k 1.4×	335 0.5×	499 0.7×	231 0.8×	480 1.8×	27	3.4k
Hwan Geun Choi South Korea	32	2.8k 1.8×	438 0.6×	289 0.4×	108 0.4×	1.1k 4.0×	77	4.2k
Stephen J. Briddon United Kingdom	32	1.9k 1.2×	145 0.2×	901 1.3×	117 0.4×	203 0.7×	87	2.6k
Sandra E. Wilkinson United Kingdom	20	1.6k 1.0×	287 0.4×	305 0.4×	134 0.4×	368 1.4×	34	2.7k
Monique Dontenwill France	32	2.0k 1.2×	225 0.3×	857 1.2×	484 1.6×	392 1.4×	123	3.0k
Richard Söll United States	23	1.2k 0.8×	490 0.7×	175 0.2×	101 0.3×	402 1.5×	75	2.7k
John C. Kath United States	19	1.5k 0.9×	905 1.2×	96 0.1×	249 0.8×	555 2.0×	30	2.4k
Heung‐Chin Cheng Australia	29	2.3k 1.4×	132 0.2×	464 0.7×	91 0.3×	359 1.3×	71	3.0k
Flora Tang United States	17	1.5k 1.0×	596 0.8×	562 0.8×	38 0.1×	518 1.9×	24	2.7k

Countries citing papers authored by Mark E. Duggan

Since Specialization

Citations

This map shows the geographic impact of Mark E. Duggan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Duggan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Duggan more than expected).

Fields of papers citing papers by Mark E. Duggan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark E. Duggan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Duggan. The network helps show where Mark E. Duggan may publish in the future.

Co-authorship network of co-authors of Mark E. Duggan

This figure shows the co-authorship network connecting the top 25 collaborators of Mark E. Duggan. A scholar is included among the top collaborators of Mark E. Duggan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark E. Duggan. Mark E. Duggan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gould, Robert W., Michael Grannan, Michael Bubser, et al.. (2017). Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M4 PAM VU0467154. Neuropharmacology. 128. 492–502. 39 indexed citations

Tarr, James C., Michael R. Wood, Meredith J. Noetzel, et al.. (2017). Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides. Bioorganic & Medicinal Chemistry Letters. 27(13). 2990–2995. 16 indexed citations

Fan, Jianjia, Wenchen Zhao, Yoko Shimizu, et al.. (2016). Identification of a Chrysanthemic Ester as an Apolipoprotein E Inducer in Astrocytes. PLoS ONE. 11(9). e0162384–e0162384. 18 indexed citations

Wood, Michael R., Meredith J. Noetzel, James C. Tarr, et al.. (2016). Discovery and SAR of a novel series of potent, CNS penetrant M4 PAMs based on a non-enolizable ketone core: Challenges in disposition. Bioorganic & Medicinal Chemistry Letters. 26(17). 4282–4286. 7 indexed citations

Sivakumaran, Sudhir, Ross A. Cardarelli, Jamie Maguire, et al.. (2015). Selective Inhibition of KCC2 Leads to Hyperexcitability and Epileptiform Discharges in Hippocampal Slices andIn Vivo. Journal of Neuroscience. 35(21). 8291–8296. 77 indexed citations

Gould, Robert W., Michael T. Nedelcovych, Michael Bubser, et al.. (2015). State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 – Relation to antipsychotic-like drug effects. Neuropharmacology. 102. 244–253. 26 indexed citations

Zhao, Zhijian, R. Robinson, Stanley F. Barnett, et al.. (2007). Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity. Bioorganic & Medicinal Chemistry Letters. 18(1). 49–53. 38 indexed citations

Lindsley, Craig W., Zhijian Zhao, William Leister, et al.. (2006). Design, Synthesis, and In Vivo Efficacy of Glycine Transporter‐1 (GlyT1) Inhibitors Derived from a Series of [4‐Phenyl‐1‐(propylsulfonyl)piperidin‐4‐yl]methyl Benzamides. ChemMedChem. 1(8). 807–811. 32 indexed citations

Wisnoski, David D., Julie A. O’Brien, Wei Lemaire, et al.. (2006). Challenges in the development of mGluR5 positive allosteric modulators: The discovery of CPPHA. Bioorganic & Medicinal Chemistry Letters. 17(5). 1386–1391. 58 indexed citations

10.

Zhao, Zhijian, William Leister, R. Robinson, et al.. (2005). Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors. Bioorganic & Medicinal Chemistry Letters. 15(4). 905–909. 125 indexed citations

11.

Kinney, Gene G., Julie A. O’Brien, Wei Lemaire, et al.. (2005). A Novel Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Has in Vivo Activity and Antipsychotic-Like Effects in Rat Behavioral Models. Journal of Pharmacology and Experimental Therapeutics. 313(1). 199–206. 229 indexed citations

12.

Duong, Le T., Carmen Fernández‐Metzler, George D. Hartman, et al.. (2005). Nonpeptide αvβ3 antagonists: identification of potent, chain-shortened 7-oxo RGD mimetics. Bioorganic & Medicinal Chemistry Letters. 15(6). 1647–1650. 12 indexed citations

13.

O’Brien, Julie A., Wei Lemaire, Marion Wittmann, et al.. (2004). A Novel Selective Allosteric Modulator Potentiates the Activity of Native Metabotropic Glutamate Receptor Subtype 5 in Rat Forebrain. Journal of Pharmacology and Experimental Therapeutics. 309(2). 568–577. 132 indexed citations

14.

Duggan, Mark E., Wasyl Halczenko, Carmen Fernández‐Metzler, et al.. (2003). Non-Peptide αvβ3 antagonists. Part 6: Design and synthesis of αvβ3 antagonists containing a pyridone or pyrazinone central scaffold. Bioorganic & Medicinal Chemistry Letters. 13(10). 1809–1812. 13 indexed citations

15.

Williams, David L., Julie A. O’Brien, Wei Lemaire, et al.. (2003). Difference in mGluR5 Interaction between Positive Allosteric Modulators from Two Structural Classes. Annals of the New York Academy of Sciences. 1003(1). 481–484. 2 indexed citations

16.

Coleman, Paul J., Ben Askew, John H. Hutchinson, et al.. (2002). Non-Peptide αvβ3 Antagonists. Part 4: Potent and Orally Bioavailable Chain-Shortened RGD Mimetics. Bioorganic & Medicinal Chemistry Letters. 12(17). 2463–2465. 26 indexed citations

17.

Barrett, Jeffrey S., Robert J. Gould, Joan D. Ellis, et al.. (1994). Pharmacokinetics and Pharmacodynamics of L-703,014, a Potent Fibrinogen Receptor Antagonist, After Intravenous and Oral Administration in the Dog. Pharmaceutical Research. 11(3). 426–431. 16 indexed citations

18.

Duggan, Mark E., Alfred W. Alberts, R. Bostedor, et al.. (1991). 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 7. Modification of the hexahydronaphthalene moiety of simvastatin: 5-oxygenated and 5-oxa derivatives. Journal of Medicinal Chemistry. 34(8). 2489–2495. 5 indexed citations

19.

Krapcho, John, Chester F. Turk, David W. Cushman, et al.. (1988). Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines. Journal of Medicinal Chemistry. 31(6). 1148–1160. 121 indexed citations

20.

Duggan, Mark E. & Donald S. Karanewsky. (1983). Preparation of optically active 2-aminoalkylphosphinic and phosphonic acids. Tetrahedron Letters. 24(29). 2935–2938. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact